Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber, Bruce E Sands, Steve Lewitzky, Marc Vandemeulebroecke, Walter Reinisch, Peter D R Higgins, Jan Wehkamp, Brian G Feagan, Michael D Yao, Marek Karczewski, Jacek Karczewski, Nicole Pezous, Stephan Bek, Gerard Bruin, Bjoern Mellgard, Claudia Berger, Marco Londei, Arthur P Bertolino, Gervais Tougas, Simon P L Travis, for the Secukinumab in Crohn's Disease Study Group
Gut Dec 2012, 61 (12) 1693-1700; DOI: 10.1136/gutjnl-2011-301668
